RT Conference Proceedings
T1 SOLTI1710 PROMETEO II: Palbociclib in combination with letrozole in hormone receptor-positive (HR+)/HER2-negative residual disease after standard neoadjuvant chemotherapy (NAC)
A1 Ciruelos, E.
A1 Salvador Bofill, F. J.
A1 Perello Martorell, A.
A1 Alba Conejo, E.
A1 Gonzalez-Farre, X.
A1 Palacios-Ozores, P.
A1 Merino, M.
A1 Villagrasa, P.
A1 Vila Navarro, E.
A1 Pascual, T.
A1 Prat, A.
A1 Pernas Simon, S.
PB Elsevier
SN 0923-7534
YR 2021
FD 2021-05-08
LK https://hdl.handle.net/10668/27091
UL https://hdl.handle.net/10668/27091
LA en
DS RISalud
RD Apr 5, 2025